Cytokinetics, Incorporated CYTK
51.65 USD -1.52 (-2.86%)
Regular-session close
51.65 0.00 0.00%
After hours · Nov 17, 4:01 PM ET
51.38 Day range 52.90
51.38 52-week range 88.31
- YTD
- -18.71%
- 1 year
- -22.85%
News
marketbeat.com Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filing Cytokinetics NASDAQ: CYTK executives said the company is seeing momentum in the launch of heart drug MYQORZO and is preparing to seek U.S. approval for its use in a second form of hypertrophic…
seekingalpha.com Cytokinetics, Incorporated (CYTK) Presents at UBS Global Biopharma Conference 2026 Transcript Cytokinetics, Incorporated (CYTK) Presents at UBS Global Biopharma Conference 2026 Transcript
globenewswire.com Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM MYQORZO is the Only Cardiac Myosin Inhibitor with Data in Its U.S. Label Comparing Its Effectiveness to the Beta Blocker Metoprolol
marketbeat.com Cytokinetics' MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Market Cytokinetics NASDAQ: CYTK executives said the launch of its heart drug MYQORZO is gaining prescribers and market share as the company prepares regulatory submissions that could expand use of…benzinga.com Cytokinetics Presents New Aficamten Data From ACACIA-HCM And FOREST-HCM At HCMS Scientific Sessions 2026 New Analyses Across Obstructive and Non-obstructive HCM Expand Clinical Evidence for AficamtenSOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK)…
benzinga.com Citigroup Maintains Buy on Cytokinetics, Raises Price Target to $105 Citigroup analyst Eric Joseph maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $99 to $105.
benzinga.com Leerink Partners Maintains Outperform on Cytokinetics, Lowers Price Target to $100 Leerink Partners analyst Roanna Ruiz maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $103 to $100.
benzinga.com Cytokinetics Q3 2026 Earnings Call Transcript Cytokinetics (NASDAQ:CYTK) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…benzinga.com Cytokinetics Q3 EPS $(1.37) Beats $(1.44) Estimate, Sales $47.557M Beat $41.879M Estimate Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.44) by 4.86 percent. This is a 11.04 percent increase over losses of $(1.54)…
benzinga.com HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $140 price target.
benzinga.com Cytokinetics Receives Notice Of Compliance From Health Canada Authorizing Treatment Use Of MYQORZO For Symptomatic Obstructive Hypertrophic Cardiomyopathy Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive…
